Want to see CLLS full AI Analyst Report?
Top Page
Cellectis SA
(NASDAQ:CLLS)
Select Model
Select Model
Rating:41Neutral
Price Target:
$2.50
▼(-11.97% Downside)
Action:Reiterated
Date:07/18/26
The score is primarily driven by weak financial performance, including steep operating/net losses, negative free cash flow, and rising leverage. Technical signals reinforce the risk with a clear downtrend (price below key moving averages) and negative momentum. Valuation provides limited support because earnings are negative (negative P/E) and no dividend yield is available.
Positive Factors
Strong early CAR‑T efficacy
Robust Phase 1 efficacy (lasme-cel 100% ORR; eti-cel 88% ORR with high CRs) in heavily pretreated patients supports a clearer path into pivotal Phase 2. Durable early clinical performance strengthens the company’s competitive positioning in off‑the‑shelf CAR‑T oncology over the medium term.
Negative Factors
Sustained cash burn
Consistent negative operating and free cash flow indicates ongoing funding needs and reliance on financing or partnerships. Sustained cash burn undermines financial flexibility, increases dilution or debt risk if milestones slip, and pressures timely conversion of clinical progress into revenue or deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong early CAR‑T efficacy
Robust Phase 1 efficacy (lasme-cel 100% ORR; eti-cel 88% ORR with high CRs) in heavily pretreated patients supports a clearer path into pivotal Phase 2. Durable early clinical performance strengthens the company’s competitive positioning in off‑the‑shelf CAR‑T oncology over the medium term.
Read all positive factors
Cellectis SA (CLLS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$205.86M
Dividend YieldN/A
Average Volume (3M)39.79K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth43.21%
EPS Growth-15.55%
CountryUS
Employees229
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.68
Shares Outstanding72,325,455
10 Day Avg. Volume15,682
30 Day Avg. Volume39,787
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)6.39
Price to Sales (P/S)6.65
P/FCF Ratio-11.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside216.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$58.43M
Cellectis SA Business Overview & Revenue Model
Company Description
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifi...
How the Company Makes Money
Cellectis generates revenue primarily through (1) collaboration and licensing arrangements and (2) service/manufacturing-related activities where applicable; it does not primarily rely on recurring product sales because it is a clinical-stage comp...
Cellectis SA Earnings Call Summary
Earnings Call Date:Aug 04, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The earnings call reflects a generally positive sentiment, driven by progress in clinical trials and strategic partnerships, despite financial and legal challenges. The successful advancement of pivotal trials and the strong collaboration with AstraZeneca are significant positives. However, the arbitration with Servier presents a notable uncertainty.Positive Updates
Pivotal Phase II Trial Initiation
Cellectis is preparing to initiate a pivotal Phase II trial for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Negative Updates
Servier Arbitration Uncertainty
Cellectis is involved in ongoing arbitration with Servier and Allogene, seeking to terminate the agreement and receive compensation for losses and milestone payments due to halted CD19 product development.
Read all updates
Q2-2025 Updates
Positive
Negative
Pivotal Phase II Trial Initiation
Cellectis is preparing to initiate a pivotal Phase II trial for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Read all positive updates
Company Guidance
During the Cellectis Second Quarter 2025 Earnings Call, the company provided extensive guidance on several key metrics and strategic initiatives. Cellectis announced plans to host an Investor R&D Day on October 16, 2025, in New York City, where they will present Phase I data and a late-stage development strategy for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia. The pivotal Phase II trial for lasme-cel is set to begin in the second half of 2025, following productive discussions with the FDA and EMA. The company also updated on their arbitration proceedings with Servier, with a decision expected by December 15, 2025. Financially, Cellectis reported a cash position of $230 million as of June 30, 2025, sufficient to fund operations into the second half of 2027. This includes the costs associated with the pivotal studies for lasme-cel and eti-cel. Additionally, the company shared progress on their collaboration with AstraZeneca, which includes three cell and gene therapy programs.Cellectis SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
38
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 68.09M | 72.95M | 41.51M | 755.00K | 19.17M | 30.35M |
| Gross Profit | 55.76M | 63.15M | 32.32M | -6.66M | 10.69M | 28.50M |
| EBITDA | -51.11M | -39.85M | -9.46M | -92.64M | -76.38M | -78.42M |
| Net Income | -67.29M | -67.59M | -36.76M | -101.06M | -106.14M | -114.20M |
Balance Sheet | ||||||
| Total Assets | 289.19M | 324.72M | 383.54M | 334.27M | 261.22M | 382.08M |
| Cash, Cash Equivalents and Short-Term Investments | 185.66M | 208.66M | 260.31M | 203.81M | 97.70M | 186.13M |
| Total Debt | 108.60M | 119.90M | 91.46M | 85.06M | 75.77M | 100.87M |
| Total Liabilities | 229.27M | 248.82M | 252.51M | 249.57M | 135.28M | 145.60M |
| Stockholders Equity | 59.92M | 75.90M | 131.03M | 84.69M | 117.97M | 221.29M |
Cash Flow | ||||||
| Free Cash Flow | -40.14M | -42.50M | 19.52M | -25.82M | -89.89M | -123.12M |
| Operating Cash Flow | -37.91M | -40.14M | 22.10M | -24.75M | -87.44M | -104.56M |
| Investing Cash Flow | -39.77M | -29.58M | -102.63M | -15.51M | -2.76M | 7.28M |
| Financing Cash Flow | -17.39M | -16.20M | 89.80M | 82.86M | 1.15M | 47.52M |
Cellectis SA Technical Analysis
Negative
2.84
Price Trends
3.02
Negative
3.36
Negative
3.74
Negative
Market Momentum
-0.08
Negative
43.05
Neutral
29.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Negative. The current price of 2.84 is above the 20-day moving average (MA) of 2.83, below the 50-day MA of 3.02, and below the 200-day MA of 3.74, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 43.05 is Neutral, neither overbought nor oversold. The STOCH value of 29.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLLS.
Cellectis SA Risk Analysis
Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cellectis SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $515.84M | -4.98 | -54.60% | ― | ― | -60.98% | |
55 Neutral | $229.18M | -1.35 | 194.13% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.15B | -0.04 | 87.31% | ― | ― | -1004.74% | |
48 Neutral | $265.97M | -3.87 | 85.78% | ― | 20.08% | 14.06% | |
44 Neutral | $160.64M | -1.58 | -80.56% | ― | ― | 59.42% | |
41 Neutral | $205.86M | -4.22 | -80.61% | ― | 43.21% | -15.55% |
* Healthcare Sector Average
CLLS
Cellectis SA
2.77
0.06
2.21%
RNAC
Cartesian Therapeutics
8.06
-3.22
-28.55%
FHTX
Foghorn Therapeutics
4.86
-0.04
-0.82%
VOR
Vor Biopharma
22.25
-19.55
-46.77%
TNYA
Tenaya Therapeutics
0.74
0.07
9.94%
ZURA
Zura Bio
5.69
4.17
274.34%
Cellectis SA Corporate Events
Cellectis Shareholders Approve 2025 Accounts and Expand Capital-Raising Powers at June 25 Meeting
Jun 25, 2026
Cellectis S.A. held its Combined General Meeting of Shareholders in Paris on June 25, 2026, where investors approved the company’s annual and consolidated financial statements for the year ended December 31, 2025, as well as the allocation o...
Cellectis Shareholders Approve Board-Backed Resolutions at June 25, 2026 Meeting
Jun 25, 2026
Cellectis S.A., a clinical-stage biotech specializing in gene-edited allogeneic CAR T-cell therapies and other cell and gene treatments, operates an end-to-end model with in-house manufacturing and facilities in Paris, New York and Raleigh. Its sh...
Cellectis Unveils Strong Early CAR-T Data for Lasme-cel and Eti-cel at EHA 2026
Jun 11, 2026
On June 11, 2026, Cellectis presented final Phase 1 results from its BALLI-01 trial of lasme-cel, a CD22-directed allogeneic CAR-T therapy, in heavily pretreated relapsed or refractory B-cell acute lymphoblastic leukemia patients at the EHA 2026 c...
Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
Jun 9, 2026
On June 9, 2026, Cellectis announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasme-cel, its CD22-targeting allogeneic CAR-T candidate for relapsed or refractory B-cell acute l...
Cellectis Calls June 25, 2026 Shareholders’ Meeting to Approve 2025 Results and Broad Capital-Issuance Powers
May 21, 2026
Cellectis S.A. has convened a combined general meeting of shareholders for June 25, 2026, at the Biopark auditorium in Paris, where investors will review the 2025 annual and consolidated financial statements, which reflect significant losses, and ...
Cellectis Sets June 25, 2026 Date for Annual Shareholders Meeting in Paris
May 20, 2026
Cellectis S.A., a clinical-stage biotechnology company specializing in gene-edited allogeneic CAR T-cell therapies and other gene therapies, leverages in-house manufacturing to control the full cell and gene therapy value chain, and is dual-listed...
Cellectis to Unveil Key Lasme-cel and Eti-cel Data at EHA 2026
May 12, 2026
On May 12, 2026, Cellectis announced it will present new clinical data on its allogeneic CAR T candidates lasme-cel and eti-cel at the European Hematology Association congress in Stockholm from June 11-14, 2026. An oral presentation will cover ful...
Cellectis Files Q1 2026 Interim Financials with U.S. SEC
May 11, 2026
Cellectis S.A. filed a Form 6-K with the U.S. Securities and Exchange Commission on May 11, 2026, furnishing its unaudited interim condensed consolidated financial statements for the three-month period ended March 31, 2026. The interim report, pre...
Cellectis Q1 2026 Results Highlight CAR-T Pipeline Milestones, New Epigenetic Platform and Licensing Dispute
May 11, 2026
On May 11, 2026, Cellectis reported first-quarter 2026 results and highlighted progress across its pipeline, including pivotal Phase 2 development of lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia and Phase 1 development ...
Cellectis to Release First-Quarter 2026 Results on May 11
May 4, 2026
Cellectis S.A., a clinical-stage biotechnology company specializing in off-the-shelf gene-edited CAR T-cell therapies and broader cell and gene therapy platforms, maintains full control of its value chain through in-house manufacturing and operate...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.